Información del artículo
El Texto completo está disponible en PDF
Biblografía
[1.]
D.H. Present, S.J. Meltzer, M.P. Krumholz, A. Wolke, B.l. Korelitz.
6-Mercaptopurine in the management of inflammatory bowel disease: short-and long-term toxicity.
Ann Intern Med, 111 (1989), pp. 641-649
[2.]
B.I. Korelitz, F.J. Mirsky, M.R. Fleisher, J.I. Warman, N. Wisch, G.W. Gleim.
Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine.
Am J Gastroenterol, 94 (1999), pp. 3248-3253
[3.]
W.R. Connel, M.A. Kamm, M. Dikson, A.M. Balkwill, J.K. Ritchie, J.E. Lennard-Jones.
Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease.
Lancet, 343 (1994), pp. 1249-1252
[4.]
W.J. Sandborn.
A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate.
Am J Gastroenterol, 91 (1996), pp. 423-433
[5.]
C.J. Haber, S.J. Meltzer, D.H. Present, B.I. Korelitz.
Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease.
Gastroenterology, 91 (1986), pp. 982-986
[6.]
C.E. Voogd.
Azathioprine, a genotoxic agent to be considered no genotoxic in man.
Mutation Res, 221 (1989), pp. 133-152
[7.]
J.D. Lewis, J.S. Schwartz, G.R. Lichtenstein.
Azathioprine for maintenance of remission in Crohn’s disease: benefits outweigh the risk of lymphoma.
Gastroenterology, 118 (2000), pp. 1018-1024
[8.]
R.G. Norfleet, C.E. Sampson.
Carcinoma of the cervix after treatment with prednisone and azathioprine for chronic active hepatitis.
Am J Gastroenterol, 70 (1978), pp. 383-384
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados
